Medpace Holdings Receives Mixed Analyst Ratings; Price Target Set

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have received a consensus recommendation of “Hold” from analysts covering the company, according to MarketBeat.com. Of the seventeen ratings firms analyzing the stock, four have issued sell recommendations, ten suggest holding, two advocate for buying, and one has assigned a strong buy rating. The average price target among these brokerages stands at $490.81 for the next twelve months.

Analyst ratings have varied significantly in recent weeks. On October 24, 2023, Cowen reaffirmed a sell rating in its research report. Following this, Truist Financial established a price objective of $555.00 on October 27. Meanwhile, Weiss Ratings upgraded Medpace to a buy (b) rating on the same day. Additionally, BMO Capital Markets began coverage of Medpace on November 13, assigning a market perform rating with a target price of $600.00. In another noteworthy development, Zacks Research elevated its rating from hold to strong buy on October 27.

Recent Financial Performance and Earnings

Medpace recently disclosed its quarterly earnings on October 22, 2023. The company reported earnings per share (EPS) of $3.86, exceeding analysts’ consensus estimate of $3.50 by $0.36. Medpace also achieved a net margin of 18.36% and a return on equity of 91.88%. Revenue for the quarter reached $659.90 million, surpassing analyst expectations of $640.49 million. Compared to the same quarter last year, revenue grew by 23.7%, when the firm reported an EPS of $3.01.

Looking ahead, Medpace has set its fiscal year 2025 guidance at an EPS range of 14.60 to 14.86. For the current year, analysts project an EPS of $12.29.

Insider Transactions and Institutional Interest

In insider trading news, Kevin M. Brady, the Chief Financial Officer, sold 3,000 shares on November 21, 2023, at an average price of $590.35, amounting to a total transaction value of $1,771,050.00. Following this sale, Brady holds 6,000 shares, valued at approximately $3,542,100. This represented a 33.33% decrease in his position.

Similarly, August J. Troendle, the Chief Executive Officer, sold 668 shares on December 3, 2023, for a total of $394,580.92. After this transaction, Troendle retained 646,184 shares valued at around $381,694,426.96, reflecting a modest 0.10% decline in ownership.

In the last quarter, insiders sold a total of 387,925 shares valued at $233,386,647. Insiders currently hold 20.30% of the company’s stock.

Several institutional investors have recently adjusted their positions in Medpace. Fifth Third Wealth Advisors LLC increased its stake by 2.6%, now owning 737 shares valued at $379,000. BOKF NA raised its holdings by 0.8%, increasing to 2,542 shares valued at $1,307,000. Other notable investments include HighPoint Advisor Group LLC, which raised its position by 2.8%, and Portside Wealth Group LLC, which increased its stake by 2.5%.

Currently, institutional investors own approximately 77.98% of Medpace’s stock, underscoring significant institutional interest in the company.

Medpace Holdings, Inc. operates as a global contract research organization (CRO), offering comprehensive clinical development services to the biotechnology, pharmaceutical, and medical device sectors. The company supports clinical trials across all phases (I–IV), providing end-to-end solutions aimed at expediting the development of new therapies. Key service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management, biostatistics, pharmacovigilance, and medical writing.